What are the side effects of Mirvetuximab soravtansine-gynx?

Mirvetuximab (Mirvetuximab In clinical studies with soravtansine-gynx), the most common (≥20%) adverse reactions (including laboratory abnormalities) include visual impairment, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, lymphopenia, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, leukopenia, neutropenia, and hemoglobinopenia.

Serious adverse reactions occurred in 31% of patients taking milvituximab, with the most common (≥2%) serious adverse reactions being intestinal obstruction, ascites, infection, and pleural effusion. Fatal adverse reactions, including small bowel obstruction and pneumonia, occurred in 2% of patients. Twenty percent of patients had milvituximab dose reductions due to adverse reactions, including visual impairment and keratopathy; 39% of patients had dose delays due to adverse reactions, including visual impairment, keratopathy, neutropenia, dry eye, cataracts, and increased gamma-glutamyl transferase. Eleven percent of patients permanently discontinued milvituximab due to adverse reactions, including ileus and thrombocytopenia. One patient permanently discontinued mivituximab due to visual impairment (unilateral decrease in BCVA to ≤20/200, which returned to baseline after drug discontinuation).

Information on the toxicity of milvituximab is unclear. Overdose patients are at increased risk for serious adverse reactions, such as ocular toxicity, pneumonitis, and peripheral neuropathy. Symptomatic and supportive measures are recommended.

Since milvituximab has been on the market for a short time, there may be less information on its price and other related information.